RESUMO
This review finds that topical corticosteroids and systemic corticosteroids are the mainstays of initial treatment for bullous pemphigoid and pemphigus diseases. Additional immunomodulatory therapies such as methotrexate, azathioprine and mycophenolatmofetil should be added early during treatment to minimize the adverse effects of chronic corticosteroid therapy and to augment improvement in the disease. Rituximab is a first-line immunomodulatory treatment for moderate to severe pemphigus disease.
Assuntos
Doenças Autoimunes , Pênfigo , Dermatopatias Vesiculobolhosas , Azatioprina/efeitos adversos , Glucocorticoides , Humanos , Metotrexato/efeitos adversos , Pênfigo/induzido quimicamente , Pênfigo/tratamento farmacológico , Rituximab/uso terapêutico , Dermatopatias Vesiculobolhosas/induzido quimicamenteRESUMO
Bullous skin diseases are characterised by a large group of diseases, where the essential clinical feature is fluid-filled skin lesions. Physicians in many different specialities can meet patients with bullous skin diseases, which include a wide range of skin diseases from mild cases to very severe and life-threating diseases. The aim of this review is to provide systematically approach of how make the accurate diagnosis, using important and basic elements of history taking, clinical and paraclinical examination.